The aggresome pathway as a target for therapy in hematologic malignancies

Area of Science:

• Cellular Biology
• Molecular Biology
• Oncology

Background:

• Misfolded proteins are managed by chaperones, the 26S proteasome, or the aggresome pathway.
• The aggresome pathway involves microtubule-organizing center (MTOC) mediated transport of proteins to lysosomes for degradation via autophagy.
• Histone deacetylase 6 (HDAC6) plays a role in this pathway by deacetylating alpha-tubulin, a component of the MTOC.

Purpose of the Study:

• To review recent findings on targeting the aggresome pathway and HDAC6 in hematologic malignancies.
• To discuss the therapeutic potential of small molecule inhibitors of HDAC6 and the aggresome pathway.

Main Methods:

• Review of recent scientific literature on HDAC6 inhibitors and the aggresome pathway.
• Analysis of studies investigating tubacin and LBH589 in hematologic malignancies.
• Examination of synergistic effects with proteasome inhibitors like bortezomib.

Main Results:

• Tubacin, an HDAC6 inhibitor, causes accumulation of polyubiquitinated proteins and apoptosis, and synergizes with bortezomib in multiple myeloma.
• LBH589, a pan-HDAC inhibitor, induces apoptosis in multiple myeloma cells resistant to conventional therapies.
• Targeting HDAC6 and the aggresome pathway demonstrates significant cytotoxicity in hematologic malignancies.

Conclusions:

• HDAC6 and aggresome pathway inhibition represent a promising therapeutic strategy for hematologic malignancies.
• Small molecule inhibitors offer potential for overcoming resistance to conventional treatments.
• Further research into these pathways could lead to novel cancer therapies.